^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | tinengotinib (TT-00420) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2- breast cancer or TNBC
Published date:
12/02/2023
Excerpt:
In 6 pts treated with tinengotinib in combination with nab-paclitaxel, one out of 2 pts with HR+/HER2- BC achieved PR for 13 weeks as of data cutoff…Tinengotinib for the treatment of HR+HER2- BC or TNBC, whether as monotherapy or in combination with nab-paclitaxel, had manageable side effects. Tinengotinib has shown promising clinical benefit in heavily pretreated pts with refractory HR+HER2- BC or TNBC.
Secondary therapy:
albumin-bound paclitaxel
Trial ID:
Source:
Title:
Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.
Published date:
05/25/2023
Excerpt:
Encouraging anticancer activity of tinengotinib monotherapy were observed in pts with heavily pre-treated solid tumors, including PC, HR+/HER2- BC, TNBC and CCA. The ongoing Ph II study of tinengotinib continues to evaluate clinical benefit and safety in pts with PC.
DOI:
10.1200/JCO.2023.41.16_suppl.3019
Trial ID:
